WVP
SCPH

Worth Venture Partners’s scPharmaceuticals SCPH Stock Holding History

Worth Venture Partners’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,283
Closed -$11.5K – 77
2024
Q1 		$11.5K Sell
2,283
-769,061
-100% -$4.31M 0.08% 56
2023
Q4 		$4.84M Buy
771,344
+231,679
+43% +$1.33M 2.61% 8
2023
Q3 		$3.84M Buy
539,665
+27,328
+5% +$215K 2.28% 7
2023
Q2 		$5.22M Buy
512,337
+1,689
+0.3% +$17.6K 2.84% 8
2023
Q1 		$4.63M Sell
510,648
-116,705
-19% -$855K 2.26% 9
2022
Q4 		$4.5M Buy
627,353
+438,831
+233% +$2.68M 2.66% 8
2022
Q3 		$1.23M Sell
188,522
-147,463
-44% -$788K 0.75% 44
2022
Q2 		$1.78M Sell
335,985
-12,440
-4% -$61.6K 1.05% 35
2022
Q1 		$1.98M Buy
348,425
+15,778
+5% +$77.5K 0.91% 43
2021
Q4 		$1.67M Buy
332,647
+31,887
+11% +$175K 0.83% 41
2021
Q3 		$2M Buy
300,760
+136,766
+83% +$817K 0.9% 39
2021
Q2 		$1M Sell
163,994
-50,066
-23% -$302K 0.37% 65
2021
Q1 		$1.42M Buy
214,060
+51,185
+31% +$351K 0.69% 43
2020
Q4 		$862K Sell
162,875
-12,651
-7% -$99.1K 0.68% 42
2020
Q3 		$1.31M Hold
175,526
– – 1.07% 22
2020
Q2 		$1.29M Buy
175,526
+31,880
+22% +$280K 0.63% 25
2020
Q1 		$1.06M Buy
143,646
+19,141
+15% +$139K 0.65% 23
2019
Q4 		$704K Buy
+124,505
New +$637K 0.34% 36

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Worth Venture Partners's SCPH Position: Q2 2024 in Review

Worth Venture Partners sold out of scPharmaceuticals (SCPH) in Q2 2024, closing a stake of 2,283 shares — an estimated $11.5K sold.

Worth Venture Partners first reported a position in SCPH in Q4 2019 and held it in 18 quarters. The position peaked at $5.22M in Q2 2023. 77 funds tracked by Wall St. Rank hold SCPH as of Q2 2024.

  • Worth Venture Partners reported no remaining scPharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Worth Venture Partners sold 2,283 scPharmaceuticals shares in Q2 2024, an estimated $11.5K.
  • Worth Venture Partners first reported a position in scPharmaceuticals in Q4 2019 and held it in 18 quarters.
  • Worth Venture Partners's scPharmaceuticals position peaked at $5.22M in Q2 2023.
  • 77 funds tracked by Wall St. Rank held scPharmaceuticals as of Q2 2024.

Based on Worth Venture Partners's 13F filing for Q2 2024, filed 14 Aug 2024.